secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0000950170-23-016245
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q1 revenue $41.6M (+162% YoY); raises FY23 guidance to $160-170M
----------------------------------------------------------------------------

- Q1 2023 revenue $41.6M (+162% YoY from $15.9M) driven by NOP adoption and OCS Liver/Heart sales.
- Gross margin 69% vs 76% in Q1 2022 and 66% in Q4 2022.
- Net loss improved to $2.6M from $10.6M in Q1 2022.
- Operating expenses $30.9M (incl. $3.9M stock comp) vs $21.5M (incl. $2.3M) in prior year.
- FY2023 revenue guidance raised to $160-170M (71-82% growth) from prior $138-145M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/0000950170-23-016245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/tmdx-20230501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-016245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer